Product image of Lafaval (Tadalafil) supplied by GNH India

Lafaval

Active Ingredient:
Tadalafil
Origin:
EU

Lafaval (Tadalafil)

Tadalafil, the active ingredient in Lafaval, is a Phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It treats erectile dysfunction and is also indicated for benign prostatic hyperplasia and pulmonary arterial hypertension in adult patients.

GNH India supplies Lafaval as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Genepharm S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lafaval, a PDE5 inhibitor, is used in several clinical conditions that involve smooth‑muscle relaxation and improved blood flow.

  • Erectile dysfunction: enhances the ability to achieve and maintain an erection suitable for sexual activity.
  • Benign prostatic hyperplasia: reduces urinary frequency and improves flow by relaxing prostate smooth muscle.
  • Pulmonary arterial hypertension: increases exercise capacity by lowering pulmonary vascular resistance.

How It Works

  • Tadalafil selectively inhibits phosphodiesterase type 5, preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to smooth‑muscle relaxation in the corpus cavernosum, prostate, and pulmonary vasculature, thereby enhancing blood flow and reducing vascular resistance in the targeted tissues.

Side Effects

Tadalafil may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Headache: mild to moderate pain in the head.
  • Flushing: warmth and redness of the face or neck.
  • Dyspepsia: indigestion or upset stomach.
  • Nasal congestion: blocked or runny nose.
  • Back pain: aching discomfort in the lower back.
  • Myalgia: muscle aches, often in the limbs.

Serious or Rare Side Effects

  • Sudden vision loss: non‑arteritic anterior ischemic optic neuropathy.
  • Sudden hearing loss: unexplained decrease in hearing acuity.
  • Priapism: prolonged erection lasting more than 4 hours.
  • Severe hypotension: marked drop in blood pressure causing dizziness.
  • Allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Chest pain: possible indication of cardiac ischemia.

Precautions & Warnings

Before prescribing Lafaval, clinicians should consider several safety aspects.

  • Cardiovascular assessment: evaluate for recent myocardial infarction or unstable angina.
  • Concomitant nitrate use: avoid due to risk of profound hypotension.
  • Severe hepatic impairment: dose adjustment may be required.
  • Renal impairment: monitor patients with moderate to severe kidney disease.
  • Retinitis pigmentosa: contraindicated in patients with this inherited retinal disorder.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Tadalafil can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Nitrates: concurrent use may cause dangerous blood‑pressure drops.
  • Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect.
  • Alpha‑blockers (certain formulations): risk of severe hypotension.

Moderate Interactions (Monitor Closely)

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole): increase tadalafil exposure.
  • CYP3A4 inducers (rifampin, carbamazepine): reduce tadalafil effectiveness.
  • Antihypertensive agents: may enhance blood‑pressure lowering.
  • Alcohol: can potentiate hypotensive effects.
  • Other PDE5 inhibitors: combined use raises risk of priapism.

Frequently Asked Questions

Lafaval contains tadalafil and is prescribed for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension. In each case the drug works by relaxing smooth muscle to improve blood flow, helping patients achieve better sexual function, relieve urinary symptoms, or increase exercise capacity respectively.

Tadalafil blocks the enzyme phosphodiesterase type 5, which normally degrades cyclic GMP. By preserving cyclic GMP levels, the drug promotes smooth‑muscle relaxation in the penis, prostate, and pulmonary arteries, leading to increased blood flow and reduced vascular resistance in those tissues.

The specific dose of Lafaval is determined by the prescribing clinician based on the patient’s condition, response, and overall health. Dosage may differ for erectile dysfunction, BPH, or pulmonary hypertension, and the prescriber will tailor the regimen to each individual.

Tadalafil is classified as pregnancy category unknown, and its safety has not been established for pregnant or nursing women. It is generally not recommended for use in these populations unless a specialist determines that the potential benefits outweigh the risks.

To request Lafaval, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lafaval (tadalafil) has a longer half‑life than sildenafil or vardenafil, allowing once‑daily dosing for BPH or a longer therapeutic window for erectile dysfunction. This can provide more flexibility for timing of sexual activity, though individual response and side‑effect profiles may differ.

Lafaval should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat, and direct sunlight to maintain potency throughout the shelf life.

Lafaval is taken orally with water. It can be taken with or without food, but a high‑fat meal may delay absorption slightly. The exact timing relative to sexual activity or other indications is guided by the prescribing clinician.

Serious risks include sudden vision loss (non‑arteritic anterior ischemic optic neuropathy), sudden hearing loss, prolonged erection (priapism), and severe hypotension, especially when combined with nitrates or certain antihypertensives. Patients should seek immediate medical attention if any of these events occur.

Lafaval is contraindicated in patients taking nitrates, those with severe uncontrolled hypertension, recent heart attack or stroke, severe hepatic impairment, and individuals with hereditary retinal disorders such as retinitis pigmentosa. A healthcare professional should evaluate suitability before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tadalafil

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT